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Abstract
Background: Colorectal cancer patients with unresectable liver-only metastases may be cured after downsizing of
metastases by neoadjuvant systemic therapy. However, the optimal neoadjuvant induction regimen has not been
defined, and the lack of consensus on criteria for (un)resectability complicates the interpretation of published
results.
Methods/design: CAIRO5 is a multicentre, randomised, phase 3 clinical study. Colorectal cancer patients with
initially unresectable liver-only metastases are eligible, and will not be selected for potential resectability. The
(un)resectability status is prospectively assessed by a central panel consisting of at least one radiologist and three
liver surgeons, according to predefined criteria. Tumours of included patients will be tested for RAS mutation status.
Patients with RAS wild type tumours will be treated with doublet chemotherapy (FOLFOX or FOLFIRI) and
randomised between the addition of either bevacizumab or panitumumab, and patients with RAS mutant
tumours will be randomised between doublet chemotherapy (FOLFOX or FOLFIRI) plus bevacizumab or triple
chemotherapy (FOLFOXIRI) plus bevacizumab. Radiological evaluation to assess conversion to resectability will
be performed by the central panel, at an interval of two months.
The primary study endpoint is median progression-free survival. Secondary endpoints are the R0/1 resection rate,
median overall survival, response rate, toxicity, pathological response of resected lesions, postoperative morbidity,
and correlation of baseline and follow-up evaluation with respect to outcomes by the central panel.
Discussion: CAIRO5 is a prospective multicentre trial that investigates the optimal systemic induction therapy for
patients with initially unresectable, liver-only colorectal cancer metastases.
Trial registration: CAIRO 5 is registered at European Clinical Trials Database (EudraCT) (2013-005435-24).
CAIRO 5 is registered at ClinicalTrials.gov: NCT02162563, June 10, 2014.
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Background
Approximately 50% of patients with colorectal cancer
(CRC) will develop metastases, either at presentation or
during follow-up. Colorectal cancer disseminates pre-
dominantly to the liver [1]. The 5-year overall survival
rates in patients with metastatic CRC have increased
over the past decades due to the availability of more
effective drugs and the increased use of resection of
metastases, and is currently around 20% [2]. Complete
resection of metastases offers the only chance for cure,
however a minority of patients (approx. 20%) present
with resectable metastases. Evidence for the benefit of
neoadjuvant chemotherapy with the objective to improve
resectability rates was already established in 1996, at
which time it was shown that initially unresectable me-
tastases could become resectable (further defined as
secondary surgery) after downsizing by chemotherapy
[3]. Currently there is consensus that combination
chemotherapy should be part of this neoadjuvant regi-
men, however there is no consensus regarding the se-
lection of targeted therapy.
Secondary liver resections after neoadjuvant systemic
treatment
Data from a single institution by Adam et al. [4] have
shown that of 1104 patients with metastases confined to
the liver, 12.5% of patients became eligible for secondary
surgery, and that these patients had a 5-year survival
rate of 33%. The benefit of primary or secondary surgery
has not been evaluated in prospective randomised studies.
However, given the consistent data from published series,
there is little doubt that a complete resection (primary or
secondary) of liver metastases prolongs survival. Indeed,
in the liver survey database the survival benefits of
secondary surgery are close to those of primary surgery,
and better than for systemic therapy alone [5].
A major problem in interpretation of the results of
these studies is the lack of consensus on the criteria for
resectability, as has been shown in the CELIM study [6].
This complicates the interpretation of the results from
studies involving patients with unresectable liver-only
metastases, and even more of the results on secondary
resection rates as reported from retrospective subgroup
analyses from phase 3 studies in unselected metastatic
colorectal cancer patients.
Choice of chemotherapy regimen in neoadjuvant
treatment
Randomised phase 3 studies have clearly shown that
combination chemotherapy with a fluoropyrimidine plus
irinotecan or oxaliplatin produces higher response rates
compared with fluoropyrimidine monotherapy [7]. There-
fore combination chemotherapy should be used when
downsizing of metastases is the primary objective.
Studies on triple chemotherapy (5FU + oxaliplatin + iri-
notecan, FOLFOXIRI) have shown high response rates
in phase-2 studies, but conflicting results on its survival
benefit in two phase-3 studies [8-10]. However, retro-
spective analysis of both phase 3 studies showed that the
rate of secondary resections was increased, from 5 (12%)
to 14 (36%) and from 6 (4%) to 14 (10%), respectively. It
should be noted that secondary resections were not a
prospective objective of these studies.
Neoadjuvant treatment with chemotherapy plus either
anti-EGFR antibodies or bevacizumab
Given the slightly higher response rates of chemotherapy
plus anti- EGFR antibodies (cetuximab, panitumumab)
compared to chemotherapy plus bevacizumab in the first-
line treatment of metastatic CRC patients, the use of cetux-
imab or panitumumab has been advocated in patients with
potentially resectable liver metastases. However, an in-
crease in the response rate has also been shown in some
(but not all) phase 3 studies by the addition of bevacizu-
mab to chemotherapy. Also high secondary R0 resection
rates were obtained in phase 2 studies with chemotherapy
plus bevacizumab [11,12]. Data from 2 randomised trials of
a head-to-head comparison between bevacizumab and
anti-EGFR therapy, both in combination with chemother-
apy, do not show a significant difference in response rate
and progression-free survival [13,14]. Also preliminary
results of the larger CALGB 80405 trial do not show a
significant difference in overall survival [15]. The results of
the TRIBE study [16] showed a significant benefit in
response rate for FOLFOXIRI + bevacizumab versus FOL-
FIRI + bevacizumab (65% versus 53%, respectively). How-
ever, this did not translate into an increased rate of
secondary resections (15% versus 12%, and in patients with
liver-only metastases 32% versus 28%, respectively).
Furthermore, the use of RECIST criteria in the evalu-
ation of the effect of targeted therapies has been ques-
tioned, and data are accumulating that morphological
criteria rather than RECIST criteria should be used to
assess the efficacy of bevacizumab treatment [17,18].
As a backbone for the use of targeted therapies, currently
no preferred chemotherapy regimen prevails. The benefit
of bevacizumab and anti-EGFR antibodies has been shown
in combination with both irinotecan- and oxaliplatin-
containing regimens [19]. A head-to-head comparison of
irinotecan- and oxaliplatin-containing regimens in combin-
ation with cetuximab has shown comparable results in pa-
tients with unresectable liver-only metastases [6]. However,
the use of capecitabine in combination with anti-EGFR
therapy is being discouraged [20].
Selection of patients for anti-EGFR therapy
Since the initial observation that KRAS mutation (exon
2, 3 en 4) is a negative predictive factor for anti-EGFR
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therapy [21], much effort has been made to further
optimize patient selection for this therapy. Recently, the
negative predictive value of RAS (KRAS exon 2,3 en4
and NRAS exon 2 and 3) mutations were confirmed
[22,23]. BRAF mutation was shown to be prognostic, but
not predictive [24,25].
Methods/design
The objective of the CAIRO5 study is to provide pro-
spectively derived data on neoadjuvant systemic treat-
ment strategies in patients with initially unresectable
colorectal cancer liver metastases while using uniform
and transparent criteria for unresectability. Given the
lack of a predictive model that allows the selection of
patients in whom a secondary resection may be
achieved, the inclusion is not limited to patients with
potentially resectable metastases and we plan to include
all patients with unresectable, liver-only metastases.
Patients with RAS wild type tumours are randomised
between bevacizumab and panitumumab in combination
with a two-drug combination chemotherapy (5-fluoro-
uracil plus either irinotecan, FOLFIRI, or oxaliplatin,
FOLFOX, according to choice of the local investigator).
Although panitumumab and cetuximab were shown
equally effective in patients with KRAS wild type tumours
[26], we selected panitumumab as anti-EGFR antibody
given the more mature data for panitumumb in relation
to RAS mutation status. Patients with RAS mutated tu-
mours will be randomised between FOLFOX/FOLFIRI
(choice of investigator) plus bevacizumab and triple
chemotherapy (FOLFOXIRI) plus bevacizumab.
An innovative aspect of CAIRO5 is the prospective as-
sessment of unresectability status and evaluation of
treatment by a central panel of radiologists and liver sur-
geons, according to predefined and transparant criteria.
Objectives and hypotheses
The primary objective of this study in CRC patients with
initially unresectable liver-only metastases is to compare
the median progression-free survival (PFS) between the
two treatment strategies in each of the two patient
cohorts (RAS wild type and RAS mutant tumors, re-
spectively). In patients with RAS wild type tumours it is
hypothesized that FOLFOX or FOLFIRI + panitumumab
will improve PFS as compared to FOLFOX or FOLFIRI +
bevacizumab. In patients with RAS mutant tumours it is
hypothesized that FOLFOXIRI + bevacizumab will im-
prove PFS as compared to FOLFOX or FOLFIRI +
bevacizumab.
Secondary objectives are to assess the secondary R0/1
resection rate, median overall survival, response rate,
toxicity, pathological response in resected lesions,
postoperative morbidity, and correlation of baseline
and follow-up evaluation by the panel with outcome.
Translational research will be performed on predictive
and prognostic biomarkers and imaging methods.
Study design
The study is designed as a randomised phase 3 trial. For
each candidate patient, a panel of at least 3 liver surgeons
and one radiologist will evaluate the baseline CT scan of
abdomen and liver for resectability or unresectability of
liver metastases (see Panel procedure and evaluation).
Potentially eligible patients will be registered after
informed consent has been obtained. Once eligibility has
been confirmed, including the unresectabilty status of
liver metastases as defined by the central panel, patients
will be randomised and KRAS (exon 2, 3 and 4), NRAS
(exon 2 and 3) and BRAF mutation status will be
assessed using TSACP MiSeq analysis [27]. Patients with
RAS wild type tumours are being randomised between
doublet chemotherapy plus either bevacizumab or pani-
tumumab. Patients with RAS mutated tumours are being
randomised between doublet chemotherapy plus bevaci-
zumab or triple chemotherapy plus bevacizumab. RAS
wild type patients and RAS mutant patients will be
randomised independently in a 1:1 ratio. Randomisation
will be done using ALEA software (ALEA®, FormsVision,
Abcoude, the Netherlands).
Patients will be stratified for potential resectability of
liver metastases (yes versus no, according to the central
panel), serum LDH (normal versus abnormal), and treat-
ment centre. Patients with RAS wild type tumours will
also be stratified for BRAF mutation status (wild type ver-
sus mutated) and use of irinotecan- versus oxaliplatin-
containing regimen. The flowchart of the study is shown
in Figure 1.
Study population
Patients who meet the following inclusion criteria are
eligible for participation in this trial: histological proof of
colorectal cancer, previously untreated and unresectable
metastases confined to the liver (as assessed by the
central panel) according to CT scan obtained less than 2
weeks prior to registration, adequate tumour tissue avail-
able for assessment of RAS and BRAF mutation status,
WHO performance status 0-1 (Karnofsky performance
status ≥ 70), age ≥ 18 years, no contraindications for liver
surgery, resectable primary tumour if still in situ, ad-
equate organ functions, life expectancy over 12 weeks,
expected adequacy of follow-up, and written informed
consent.
Exclusion criteria are: previous systemic treatment
for metastatic disease, extrahepatic metastases, with
the exception of small (≤1 cm) extrahepatic lesions
that are not suspicious of metastases, unresectable
primary tumour, serious comorbidity or any other
condition preventing the safe administration of study
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treatment (including both systemic treatment and sur-
gery), major cardiovascular event within 12 months be-
fore randomisation, uncontrolled hypertension, or
unsatisfactory blood pressure control with ≥3 antihy-
pertensive drugs, previous adjuvant treatment unless
completed ≥ 6 months prior to randomisation, previous
surgery for metastatic disease, previous intolerance of
study drugs in the adjuvant setting, pregnant or lactat-
ing women, second primary malignancy within the past
5 years with the exception of adequately treated in situ
carcinoma of any organ or basal cell carcinoma of the
skin, any concomitant experimental treatment.
Panel procedure and evaluation
A central panel consisting of at least 3 liver surgeons and
one radiologists will review the CT scans for resectability
status prior to randomisation and at first evaluation (after
4 treatment cycles), and, if deemed necessary, at second
evaluation (after 8 treatment cycles), and at third evalu-
ation (after 12 treatment cycles). The central panel is
blinded for the treatment arm. Any further review will
take place according to panel decision.
By general consensus among Dutch hepatic sur-
geons, and for purpose of transparency and uniformity,
unresectability at baseline for this study is defined as
the expected failure of achieving a complete (R0) re-
section of all lesions in one single surgical procedure
(i.e. excluding 2-stage resections, use of portal vein
embolization) by surgical resection only (i.e. excluding
the use of RFA or other surgical methods), leaving a
minimum remnant liver volume of 25-30% in normal
livers, and 35-40% in compromised livers (fibrosis, cir-
rhosis or steatosis).
Once a patient has entered the study following these
criteria, the central panel will evaluate resectability of
liver metastases after every 4 treatment cycles (now also
allowing the use of preoperative portal vein embolization
and the combination with local ablative techniques such
as RFA, or of a two-stage resection). The decision of re-
sectability will be made by the central panel by majority
vote. The chairman of the panel will coordinate the voting
process and confirm final decision of the panel. Secondary
resection should include all lesions as demonstrated at
baseline imaging, however, when lesions have disappeared
under treatment and are not detectable during the surgical
procedure, these will be left in situ. The decision to
perform secondary resection by laparoscopic or by open
procedure is left to the discretion of the performing
surgeon.
Patients’ images will be uploaded in a software pro-
gram specially designed to share patient imaging in a
safe and privacy-respecting environment. (ALEA®, For-
msVision, Abcoude, the Netherlands).
Study treatment: systemic therapy
Patients will be treated according to the assigned treat-
ment regimen. All systemic treatment regimens are ad-
ministered according to standard practice, and all cycles
have a length of 2 weeks. The choice between FOLFIRI
and FOLFOX is at the discretion of the local investigator
and may be selected on a per patient basis.
The assigned treatment will be continued for at least 6
months (12 cycles) or until progression of disease, un-
acceptable toxicity, or patient refusal. If after 6 months
the liver metastases are still not resectable it is highly
unlikely that resectability will be achieved at all. These
Figure 1 Study design CAIRO5.
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patients have liver metastases that remain unresectable
after induction systemic therapy, however without pro-
gression of disease. They should continue with the tar-
geted drug in combination with chemotherapy, but the
chemotherapy should be continued as maintenance
treatment with 5FU/LV alone. The targeted drug should
not be replaced by any other targeted drug during first-
line treatment prior to disease progression.
Treatment after first progression is not part of the
study, however recommended strategies can be found in
the study protocol.
In patients who become resectable and undergo sec-
ondary surgery of their liver metastases, the total dur-
ation of preoperative and postoperative treatment
together should be 6 months, with the chemotherapy
schedule being continued postoperatively according to
the preoperative schedule. However, given the lack of
benefit of adding a targeted drug to chemotherapy in the
adjuvant setting of stage III colon cancer [28-30] as well
as of resected liver metastases [31], the targeted drug
will not be continued after surgery.
Study statistics, sample size, planned analyses
The study is designed as a randomised phase 3 trial with
progression free survival (PFS) as its primary endpoint.
Two hypotheses will be tested simultaneously:
– in patients with RAS wild type tumours it is
hypothesized that FOLFOX or FOLFIRI +
panitumumab will improve PFS as compared to
FOLFOX or FOLFIRI + bevacizumab.
– in patients with RAS mutant tumours it is
hypothesized that FOLFOXIRI + bevacizumab will
improve PFS as compared to FOLFOX or FOLFIRI
+ bevacizumab.
Given recent literature, it is expected that approxi-
mately 45% of the patients will have RAS (KRAS and
NRAS) wild type tumours while 55% will have RAS mu-
tated tumours.
The median PFS in patients with RAS wild type and
RAS mutant tumours is estimated to be 10 months. The
treatment is assumed to reduce the hazard rate for PFS
by 30%. To detect such an improvement in PFS with
80% power and a two-sided logrank test at 5%, 247
events need to be observed. This requires an inclusion
of approximately 640 patients, which are expected to be
accrued in 4 years.
For the primary endpoint of PFS two interim analyses
and a final analysis will be performed, equally spaced
based on the number of events (approximately at one-
third, two-third) of the way through the trial. At the in-
terim analysis both futility and efficacy will be consid-
ered. The trial may be discontinued in either subgroup
(RAS wild type and RAS mutated patients) when the
treatment is very efficacious, but the trial may also be
discontinued early in either subgroup if the new treat-
ment is unlikely to show superiority to control based on
the interim analysis.
Analysis of the primary endpoint will be based on the
‘intention-to-treat’ population. PFS by treatment arm
will be calculated and depicted by means of the Kaplan
Meier technique and will be compared using the (strati-
fied) logrank test. Hazard ratios and 95% confidence inter-
vals will be calculated with a (stratified) cox-proportional
hazard analysis.
Quality
Data management will be centrally and locally provided
by the clinical research department of the Comprehensive
Cancer Center in the Netherlands (IKNL).
This study will be monitored based on the recommen-
dations as described in the brochure “Kwaliteitsborging
mensgebonden onderzoek 2.0” published October 2012
by the Dutch Federation of University Medical Centres
(NFU). Independent qualified monitors, local and central
oncology data managers of IKNL clinical research de-
partment, will monitor the trial.
Safety
In accordance to section 10, subsection 1, of the W.M.O.
(Wet Medisch-wetenschappelijk Onderzoek met mensen),
the investigator will inform the subjects and the reviewing
accredited Medical Ethical Committee if anything occurs,
on the basis of which it appears that the disadvantages of
participation may be significantly greater than was fore-
seen in the research proposal. It is mandatory to record
and report all serious adverse event (SAEs). The local in-
vestigators are responsible for reporting SAEs. All SAEs
must be reported within 24 hours. The DCCG as the initi-
ator is responsible for SAE assessment and reporting to
the authorities in accordance with all requirements of the
Dutch law. The DCCG has delegated these responsibilities
to the principal investigator of this study. The sponsor will
submit, once a year throughout the clinical trial, a safety
report to the accredited Medical Ethical Committee, com-
petent authority, and competent authorities of the con-
cerned Member States.
In the CAIRO5 a Data Safety Monitoring Board
(DSMB) is established to perform ongoing safety sur-
veillance and to perform interim analyses on the safety
data. This committee is an independent committee.
The advice(s) of the DSMB will only be sent to the
sponsor of the study. Should the sponsor decide not to
fully implement the advice of the DSMB, the sponsor
will send the advice to the reviewing METC, including
a note to substantiate why (part of ) the advice of the
DSMB will not be followed.
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Ethics
This study will be conducted in accordance to the stan-
dards of Good Clinical Practice, in agreement with the
Declaration of Helsinki (latest amendment), Dutch law
in general and with the W.M.O. in particular.
The study has been approved by the medical ethical
committee of the Academic Medical Centre Amsterdam,
The Netherlands.
Discussion
Secondary resection of liver metastases offers the only
chance for cure in patients with initially unresectable, liver-
only metastases. However data on secondary resection rates
of initially unresectable colorectal cancer liver metastases
are difficult to interpret. Most of these data are derived
from retrospective studies, without data on outcome.
There are no data from prospective studies with trans-
parent and uniform criteria for staging and resectability
in patients with initially unresectable liver-only metasta-
ses. In the past, resectability of colorectal liver metasta-
ses has been based on tumour characteristics in the
absence of extra-hepatic disease, such as the number of
metastases, bilobar distribution, size of the largest metas-
tasis and synchronicity. With improved treatment results
and strategies these criteria have been modified. Currently,
patients are selected on the basis of feasibility of achieving
R0 resection with preservation of sufficient remnant liver
to support metabolic liver function. Most surgeons will
rely on a minimum of 25-30% of remnant liver, while
maintaining adequate portal venous and hepatic arterial
perfusion, hepatic venous drainage and biliary drainage.
Furthermore, based on the currently available data
there is no outright preference for the use of either beva-
cizumab or anti-EGFR antibodies in combination with
chemotherapy in patients with (K)RAS wild type tu-
mours in whom secondary resection of metastases is the
primary objective. Although its results are promising,
triple chemotherapy with FOLFOXIRI has not shown to
be outright superior in this respect to doublet regimens
with FOLFOX or FOLFIRI.
In view of the considerations above, we elected to use
clear-cut criteria for unresectability in the CAIRO5
study. Although by no means we consider these as the
most optimal criteria, the transparent and reproducible
nature of these criteria do allow to select a homoge-
neous patient population in terms of liver involvement,
which subsequently facilitates the interpretation of our
data. This is further supported by the use of a central
panel that prospectively evaluates the status of liver
metastases according to these criteria in all patients. We
expect that the results of the CAIRO5 trial will contribute
to define the optimal strategy in patients with initially
unresectable, liver-only colorectal cancer metastases. The
study is open for accrual as of July 2014.
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